作为潜在的癌症化学治疗药物,Dynemicin A衍生物通过突变合成
Paramita Pal1, Jamie R Alley1, Douglas R Cohen1
1Department of Chemistry, Remsen Hall, The Johns Hopkins University, 3400 North Charles St., Baltimore, MD 21218, USA.
研究人员开发了一种突变合成策略,以创造新的抗瘤抗生素. 这种方法允许进行化学修饰,可能增强它们的抗癌特性和治疗开发.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 恩迪恩抗瘤抗生素具有强大的DNA裂变能力,使其成为有前途的癌症治疗药物.
- 它们的复杂结构和高反应性对临床生产和开发构成重大挑战.
研究的目的:
- 探索一种突变合成策略,用于制造修饰后的抗生素.
- 为了实现关键生物合成中间体的特定修饰的化学合成.
- 为了克服临床开发基于enediyne的癌症治疗方法的挑战.
主要方法:
- 使用一种突变合成方法,将化学合成与生物生产相结合.
- 雇佣了一个突变的细菌生产者,无法合成一个关键的甲-γ-thiolactone中间体.
- 化学上补充了突变体的合成结构类似物,用于前体导向生物合成.
主要成果:
- 成功地生产了动氨基素A衍生物,在氨基A环上进行了替代.
- 开发了一种阻断Dorf15的突变物,以及对甲变体的合成途径.
- 通过使用外部供应的类似物,证明了有效的前体导向生物合成.
结论:
- 突变合成策略使得创建新型基因结构成为可能.
- 修改后的enediynes可能会增强DNA结合并调整生物修复性激活.
- 这种方法有助于开发改进的基于enediyne的癌症治疗方法.
更多相关视频
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
相关概念视频
Mutagenicity and Carcinogenicity
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Destabilize Microtubules
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
